Quote this publication Share Print

CONCERTA LP

-
Opinions on drugs - Posted on Feb 06 2013

Reason for request

Re-assessment of methylphenidate-based proprietary products in attention-deficit hyperactivity disorder in response to a request from the Directorate-General for Health.

-


Actual benefit

Important

The actual benefit of CONCERTA LP proprietary products is substantial in the context of the overall therapeutic management of ADHD in children aged 6 years and over when psychological, educational and social management alone prove insufficient.


Contact Us

Évaluation des médicaments

See also